BidaskClub downgraded shares of Veracyte (NASDAQ:VCYT) from a buy rating to a hold rating in a research report report published on Wednesday, December 4th, BidAskClub reports.
Other analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Veracyte from a buy rating to a hold rating in a report on Friday, November 8th. Needham & Company LLC restated a buy rating and set a $34.00 target price on shares of Veracyte in a report on Monday, November 18th. Finally, ValuEngine raised Veracyte from a sell rating to a hold rating in a research report on Thursday, October 31st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $28.75.
NASDAQ:VCYT opened at $29.10 on Wednesday. The stock has a market cap of $1.46 billion, a P/E ratio of -46.94 and a beta of 1.14. The firm’s fifty day simple moving average is $27.51 and its 200 day simple moving average is $26.39. Veracyte has a twelve month low of $11.70 and a twelve month high of $31.18.
Veracyte (NASDAQ:VCYT) last released its quarterly earnings results on Tuesday, October 22nd. The biotechnology company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.05. Veracyte had a negative net margin of 7.08% and a negative return on equity of 5.33%. The business had revenue of $30.97 million for the quarter, compared to analysts’ expectations of $30.41 million. Analysts predict that Veracyte will post -0.19 earnings per share for the current fiscal year.
In other Veracyte news, CEO Bonnie H. Anderson sold 8,000 shares of the business’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $24.50, for a total transaction of $196,000.00. Following the completion of the sale, the chief executive officer now directly owns 109,467 shares in the company, valued at approximately $2,681,941.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Evan/ Fa Jones sold 15,000 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $29.26, for a total value of $438,900.00. Following the sale, the director now owns 25,000 shares of the company’s stock, valued at $731,500. The disclosure for this sale can be found here. In the last ninety days, insiders sold 129,486 shares of company stock valued at $3,479,894. 8.30% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management & Equity Research Inc. increased its stake in Veracyte by 3.5% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,535 shares of the biotechnology company’s stock worth $329,000 after purchasing an additional 390 shares during the period. Convergence Investment Partners LLC boosted its position in Veracyte by 13.3% during the third quarter. Convergence Investment Partners LLC now owns 5,918 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 695 shares in the last quarter. Strs Ohio raised its stake in Veracyte by 2.8% in the third quarter. Strs Ohio now owns 32,800 shares of the biotechnology company’s stock valued at $787,000 after buying an additional 900 shares during the last quarter. Advisor Group Inc. purchased a new stake in Veracyte in the second quarter valued at about $29,000. Finally, Tower Research Capital LLC TRC raised its stake in Veracyte by 1,433.3% in the third quarter. Tower Research Capital LLC TRC now owns 1,150 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,075 shares during the last quarter.
About Veracyte
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
See Also: How to build a Fibonacci channel
Receive News & Ratings for Veracyte Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Veracyte and related companies with MarketBeat.com’s FREE daily email newsletter.
